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nificant decrease after 6 months on raloxifene that persistedEffect of raloxifene on bone metabolism and serum lipids in
thereafter. Low-density lipoprotein (LDL)-cholesterol decreasedpostmenopausal women on chronic hemodialysis.
significantly in the raloxifene group with no changes in serumBackground. Premature amenorrhea and hypoestrogenism
triglycerides, total cholesterol, or HDL cholesterol. No signifi-and lack of hormone replacement therapy after menopause have
cant side effects were observed in the raloxifene group.been frequently reported in uremic women on dialysis. There-
Conclusion. The study demonstrates that after one year onfore, in addition to renal osteodystrophy, postmenopausal
raloxifene, postmenopausal women on hemodialysis have a sig-women on dialysis could be at risk of osteoporosis. In addition,
nificant increase in trabecular BMD, decrease in bone resorptionthese patients are at higher risk for hyperlipidemia, arterioscle-
markers and LDL-cholesterol values, suggesting that SERMsrosis, and subsequent coronary heart disease and stroke. Re-
could constitute a therapeutic alternative to improve bone me-cent evidence has suggested that hormone replacement therapy
(HRT) in postmenopausal women could have several beneficial tabolism and control of hyperlipidemia in these patients. The
effects as well as potentially serious risks. Great efforts have possible long-term effects of raloxifene remain to be deter-
been made to identify therapeutic alternatives that would have mined.
the benefits of estrogen on brain and bone without its adverse
effects on breast and endometrium. In the present study, we
evaluated the effect of raloxifene, a selective estrogen receptor
Postmenopausal uremic women, including those onmodulator (SERM), on bone metabolism and serum lipids in
chronic hemodialysis, are at risk of developing uremicpostmenopausal women on chronic hemodialysis.
Methods. We performed a prospective, blind, placebo-con- bone disease and postmenopausal osteoporosis [1, 2].
trolled, and randomized study. Fifty postmenopausal women Nevertheless, postmenopausal osteoporosis has not been
on chronic hemodialysis with proven severe osteopenia or os-
accounted as an important determinant of uremic boneteoporosis by bone densitometry were selected. After a written
disease and the issue of hormone replacement therapyinformed consent, patients were randomized into two groups:
25 women on placebo and 25 women on the study drug, raloxi- (HRT) is not usually discussed between the patients and
fene hydrochloride, at a dose of 60 mg/day. In all patients, we their physicians [3]. The fact that hypoestrogenism initi-
performed a baseline bone mineral density (BMD) analysis ates early after renal failure makes this situation more
and simultaneously evaluated different biochemical parameters,
difficult. In a previous study from our laboratory, weserum lipids (total low-density lipoprotein [LDL] and high-
found that an important group of young uremic womendensity lipoprotein [HDL] cholesterol and triglycerides) and
serum markers of bone resorption (pyridinoline crosslinks). on dialysis have early amenorrhea, relative hypoestro-
BMD was reassessed after 1 year of therapy. Bone resorption genism, and decreased bone mass when compared to simi-
markers were determined every 3 months for 1 year. lar women with regular menstruation [4]. These young
Results. After 1 year on raloxifene therapy, lumbar spine
women on dialysis (younger than 50 years old) showedBMD (trabecular bone) significantly improved, whereas femo-
decreased trabecular bone mineral density (BMD), andral neck BMD (cortical bone) did not change significantly. No
changes in BMD were observed at trabecular or cortical sites elevation on bone resorption markers.
in the placebo group. Serum pyridinoline levels showed a sig- Only a small proportion of postmenopausal women
with chronic renal disease are being offered HRT; there-
fore, menopause in women on dialysis is not managedKey words: osteoporosis, bone mineral density, hemodialysis, hormone
replacement therapy, SERM, raloxifene. in the same way as in normal women. This brings into ac-
count another aspect regarding the pharmacokinetics ofReceived August 31, 2002
exogenous estradiol in uremia. Recent work by Ginsburgand in revised form November 16, 2002
Accepted for publication January 16, 2003 et al [5] demonstrated that when compared to normal
postmenopausal controls, uremic women had elevated 2003 by the International Society of Nephrology
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estradiol levels at baseline, which increased significantly signed to a drug group (oral raloxifene, 60 mg/day, N 
to higher values after the ingestion of a single dose of 25) or placebo (N  25).
micronized estradiol. Baseline blood determinations and BMD analysis
The issue of HRT with opposed estrogen-progester- were obtained. Blood was drawn every 3 months and
one therapy in uremic women is still controversial, espe- BMD was reassessed after 1 year.
cially after the recent report in normal postmenopausal
Biochemical assayswomen of increased risk of breast cancer, pulmonary em-
bolism, and coronary and cerebrovascular disease after a Serum levels of total calcium, phosphorus, alkaline
long-term combination of estrogen and progesterone [6]. phosphatase, blood urea nitrogen (BUN), and creatinine
On the contrary, treatment with raloxifene, a selective were analyzed at baseline and every 3 months by standard
estrogen receptor modulator (SERM), with a spectrum photometric methods. Hormone levels of total estradiol,
of tissue-specific agonist-antagonist effects on estrogen follicle-stimulating hormone (FSH), and luteinizing hor-
target tissues but acting also on bone as an estrogen mone (LH) were assayed at baseline by chemilumines-
agonist, seems a less harmful and more rational thera- cence with an Elecsys 1010 (Boehringer Mannheim GmbH
peutic strategy [7]. In the large Multiple Outcomes of Diagnostic, Mannheim, Germany). Serum lipids [total
Raloxifene Evaluation (MORE) trial of 7705 women cholesterol, low-density lipoprotein (LDL) and high-
with osteoporosis, 3 years on raloxifene treatment on density lipoprotein (HDL) cholesterol and triglycerides]
doses of 60 mg/day increased BMD at the lumbar spine were determined by an enzymatic method using an auto-
by 2.7% with large decreases in vertebral fractures of analyzer (Ciba Corning A-550 Express, Bayer Co., Tarry-
41%, with no reduction on hip or other nonvertebral town, NY, USA). Serum parathyroid hormone (PTH) was
fractures [8]. Similarly, raloxifene has been shown to determined by an immunoradiometric assay (Allegro,
decrease serum lipid values in postmenopausal women Nichols Institute Diagnostics, San Juan Capistrano, CA,
[9, 10]. This change in the lipoprotein profile could be USA). Determination of pyridinoline crosslinks in se-
relevant in patients on dialysis, since cardiovascular dis- rum, a marker of bone resorption, was performed at
ease is the single best predictor of mortality in patients baseline and every 3 months for 1 year by enzyme-linked
with end-stage renal disease (ESRD), as it accounts for immunosorbent assay (ELISA) (Metra Serum PYD,
almost 50% of deaths [11]. Quidel Corp., San Diego, CA, USA).
For these reasons, we designed a 1-year prospective,
controlled, and double-blind study on the effect of raloxi- Bone mineral measurements
fene on bone and lipid metabolism on postmenopausal BMD of the lumbar spine and femoral neck were per-
women on hemodialysis with severe osteopenia.
formed by dual x-ray absorptiometry (DEXA), with a
DPX-L densitometer (Lunar Corporation, Madison, WI,
METHODS USA). The results were expressed in grams and divided
by the projected area of the bone to derive the BMD inPatients
grams per square centimeter. In order to evaluate patientsFrom a total of 276 patients under treatment in the
of different ages, we used the Z score, which comparesdialysis units of the University Hospital of Caracas and
the value of every patient with an age- and gender-matchedFresenius Medical Care of Venezuela, 120 women were
control population and the T score that compares theevaluated. From these patients, 50 women were selected
BMD to gender-matched young adults. The precisionaccording to the following criteria: (1) age older than
error of the BMD analysis in our laboratory was 0.7%50 years, (2) longer than 2 years of menopause, and (3)
for the whole body, 1% for anteroposterior spine, andevidence of severe osteopenia or osteoporosis according
0.7% for the femoral neck [12].to the World Health Organization (WHO) criteria (T score
below 2.0 SD). The following exclusion criteria were
Side effectsapplied: no history of previous HRT, diabetes, venous
Side effects such as arteriovenous fistulas, grafts, or di-occlusive disease, previous history of arteriovenous fis-
alysis catheter thrombosis, evidence of superficial throm-tula thrombosis, hepatic disease, or cancer.
bophlebitis, or venous thromboembolism, and increasedNone of the patients had previous evidence of disease,
vasomotor symptoms were assessed every month through-other than chronic renal failure, that could affect bone
out the study.metabolism. Patients who had been recently treated with
estrogen, progesterone, tibolone, corticosteroids, anti-
Statistical analysisconvulsants, fluoride, bisphosphonates, or calcitonin were
Results are presented as mean  SD. Comparisons be-excluded from the study.
tween two groups of data were performed by StudentThe study was approved by the Ethics Committee of
t test for paired observations (two-tailed). A P value ofthe Hospital Universitario de Caracas. After an informed
consent was obtained, the patients were randomly as- 0.05 was considered significant.
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Table 2. Serum biochemical parameters at baseline in hemodialyzedTable 1. Age, time on dialysis, and lumbar spine and femoral neck
T score in control and raloxifene women (mean  SD) women on placebo or raloxifene (mean  SD)
Placebo RaloxifenePlacebo Raloxifene
Serum values (N  25) (N  25)
Number of patients 25 25
Age (meanSD) years 61.98.7 63.18.6 Creatinine mg/dL 11.33.1 10.72.1
Calcium mg/dL 9.060.71 9.250.89Time on dialysis (meanSD) months 69.0940.1 74.8135.7
T Score lumbar spine SD 2.520.74 2.510.72 Phosphorus mg/dL 4.70.9 5.11.8
Estradiol pg/mL 25.317.3 24.29.9T Score femoral neck (meanSD) SD 1.990.25 2.150.27
FSH mIU/mL 95.227.3 78.346.7
Luteinizing hormone mIU/mL 65.322.6 52.0218.9
iPTH pg/dL 382.8147 321163
RESULTS Alkaline phosphatase IU/L 113.561 121.253
Pyridinoline crosslinks 35.8413.55 36.318.59Fifty of the 120 women on hemodialysis at our centers
Abbreviations are: FSH, follicle stimulating hormone; iPTH, intact parathy-fulfilled the criteria and agreed to participate in the study. roid hormone.
Women randomized to the raloxifene or placebo groups
were similar regarding age, time on dialysis, time after
menopause, and medical management of renal osteodys- No side effects, including thrombophlebitis, venous
trophy (Table 1). The patients were selected by the pres- thromboembolism, clotting problems with the vascular
ence of severe osteopenia or osteoporosis with a mean accesses or increased vasomotor symptoms, were ob-
T score of2.52 0.74 in the placebo group and2.51 served during treatment with raloxifene.
0.72 in the raloxifene group (NS). Similarly, the femoral
neck T score was 1.99  0.25 and 2.15  0.27, in the
DISCUSSIONplacebo and raloxifene groups, respectively (NS).
Our results demonstrate that postmenopausal womenBlood biochemical parameters are shown in Table 2.
on dialysis with severe osteopenia or osteoporosis sig-Serum creatinine, calcium, and phosphorus were similar
nificantly benefited in terms of BMD and serum lipidin both groups. Sexual hormone levels (total estradiol,
values after 1 year on raloxifene.FSH, and LH) were similar in both groups, showing the
Previous studies from our laboratory have demon-usual postmenopausal pattern of lower total estradiol
strated that young amenorrheic and relatively hypoestro-and higher FSH. Serum PTH values were increased to
genic women have significantly lower BMD and higherthe same extent in both groups, but not significantly
bone resorption markers, compared with similar patientsdifferent between groups. Bone-specific alkaline phos-
with normal menstruation, suggesting that estrogen lev-phatase and serum pyridinoline were similar at baseline
els could be in part responsible for the maintenance ofin both groups.
the bone metabolism in these subjects [4]. Women withBMD at the lumbar spine improved significantly after
chronic renal disease are frequently hypoestrogenic as1 year of treatment with raloxifene. As shown in Table 3,
a result of the disease or its treatment. In a recent study,Z and T scores for lumbar spine improved significantly
Cochrane and Regan [13] questioned 100 women within the raloxifene group with no significant changes in
chronic renal failure (26 of them on chronic dialysis)the placebo group. There was a 2.3% improvement in
about various gynecologic aspects. Menstrual disordersthe lumbar spine T score after 1 year on raloxifene with
were present in 85% of the patients. Menopause wasa 0.3% decrease in the placebo group (P  0.01). Femo-
found in one third of the patients, but only two of theseral neck BMD, Z, or T scores did not change significantly
women (6%) were on HRT. Another study evaluatingin both comparison groups.
women on dialysis younger than 55 years of age foundFigure 1 shows the percentage changes from the base-
that 58% were amenorrheic and 28% postmenopausal.line in serum pyridinoline measured every 3 months in
However, only one patient in the postmenopausal womenboth groups. After 6 months, there was a significant de-
group was receiving HRT [3]. Similar results were ob-crease in the serum pyridinoline values in the raloxifene
served in our dialysis population [14]. From 127 womengroup, as compared to the placebo group. The decrease was
on dialysis, 53 were postmenopausal and older than 50of 25%, 39%, and 35% at 6, 9, and 12 months, respectively.
years of age, and only six of them were on regular HRTBlood levels of total cholesterol, HDL-, and LDL-
(11.3%). Thus, only a few postmenopausal women arecholesterol and serum triglycerides were also determined
being offered HRT, indicating that these patients areat baseline and after 1 year on the drug or placebo.
managed differently than nonuremic women. BesidesAs shown in Table 4, a significant decrease in LDL-
the lack of awareness of the treating physicians, womencholesterol values was observed after 6 months in the
with ESRD are usually stoic and rarely complain aboutraloxifene group. No significant changes in serum total
gynecologic problems that may seem trivial in compari-cholesterol or triglycerides were demonstrated in both
son to their renal disease.groups. A slight increase in HDL-cholesterol (P  0.05)
was observed at 12 months in raloxifene-treated patients. The adverse effects of hypoestrogenism on bone have
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Table 3. Bone mineral density (BMD), Z and T scores at lumbar spine (L2–L4) and femoral neck in the placebo and raloxifene groups,
before and after 1 year of treatment (mean  SD)
Placebo (N  25) Raloxifene (N  25)
Month 0 Month 12 Month 0 Month 12
L2–L4 BMD g/cm2 0.9520.041 0.9490.05 0.9420.041 0.9730.043a
L2–L4 Z score 0.610.26 0.630.31 0.640.33 0.560.34a
L2–L4 T score 2.520.74 2.560.73 2.510.72 2.450.84a
Femur BMD g/cm2 0.7450.03 0.7430.04 0.7220.03 0.7270.04
Femur Z score 0.6300.26 0.6490.27 0.8000.26 0.7610.32
Femur T score 1.990.25 2.00.32 2.150.27 2.110.36
a P  0.01 (two-tailed, paired Student t test)
been widely recognized. Lack of estrogens is associated
with increased osteoclastic bone resorption, probably by
a direct effect, as well as by stimulating the production
of bone-resorting cytokines such as interleukin-1 (IL-1),
IL-6, IL-11, and tumor necrosis factor- (TNF-) [15–18].
In addition, estrogens may affect PTH action by increas-
ing PTH mRNA at the parathyroid gland [19] and modu-
lating PTH action on bone. Indeed, studies in vitro have
demonstrated that estrogen inhibits PTH-stimulated osteo-
clast formation by directly affecting hemopoietic blasts
cell precursors by a cyclic adenosine monophosphate
(cAMP)-mediated mechanism [20]. Clinical evidence sup-
porting the role of estrogen in uremic bone disease in
women has been recently advanced by Matuszkiewicz-
Rowin˜ska et al [21]. In that controlled study of a small
group of postmenopausal dialysis women, the treatment
with transdermal estradiol and cyclic addition of nores-
Fig. 1. Mean (SD) percentage changes from baseline in serum pyridi-tisterone acetate significantly increased lumbar spine
noline crosslinks levels in postmenopausal hemodialyzed women given
BMD after 1 year [21]. Another health risk of estrogen raloxifene (60 mg/day) () or placebo () for 1 year. *P  0.01 vs.
placebo.deficiency is the excessive cardiovascular morbidity and
mortality observed in uremic patients. In a recent article,
Ginsburg et al [22] demonstrated that HRT in 11 post-
menopausal women with ESRD increased HDL-choles-
terol significantly, to an extent that would be expected we have to consider that total and free estradiol levels
to improve cardiovascular risk profile. are higher at baseline and after estradiol administration
Nevertheless, estrogen therapy in postmenopausal in patients with ESRD when compared to the normal
women could have several beneficial effects as well as renal function patients [5], suggesting that renal failure
potentially serious risks. At the present time there are may decrease estradiol catabolism and affect the phar-
no long-term studies in uremic women on hemodialysis macokinetics of exogenous estradiol.
or continuous ambulatory peritoneal dialysis (CAPD) Several alternatives are available for women who can-
that support the recommendation of HRT to all post- not or refuse to take estrogen. Two potential estrogen-
menopausal women. A recent study on the risks and bene- like therapies include raloxifene and tamoxifen. These
fits of estrogen plus progestin in healthy postmenopausal SERMs possess tissue-selective estrogen agonist and an-
women (Women’s Health Initiative) has introduced a tagonist properties [23]. Efforts have been made to de-
word of caution in HRT therapy [6]. In this randomized, sign drugs that have estrogen activity in bone and cardio-
controlled, primary prevention trial, the estrogen plus vascular tissue but not in reproductive tissue [24]. Raloxi-
progestin treatment reduced the observed hip and verte- fene is an example of such a drug. In ovariectomized
bral fracture rate and colon cancer by one third. Never- animals, raloxifene preserves bone density, lowers serum
theless, the rate of women experiencing coronary hearth total cholesterol concentrations, and inhibits aortic cho-
disease increased by 29%, venous thromboembolism was lesterol accumulation, without causing endometrial hy-
twofold greater, stroke rates were increased by 41%, perplasia [25]. The mechanism responsible for the appar-
ent tissue-selective activity of raloxifene is incompletelyand invasive breast cancer increased by 26%. In addition,
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Table 4. Lipid values in the placebo and raloxifene groups (mean  SD)
0 3 months 6 months 9 months 12 months
Total cholesterol placebo 191.633.7 19842 187.552 22871 189.255
LDL-cholesterol placebo 143.729.1 14934 14235.1 13641 148.135
HDL-cholesterol placebo 37.68.02 389.2 4615.3 47.615 3512.1
Triglycerides placebo 201.560.3 18666 21071 18950.8 19953.2
Total cholesterol raloxifene 197.032.5 195.134.5 193.229.5 193.233.5 189.129.5
LDL-cholesterol raloxifene 138.143.7 135.119.2 130.332.3a 128.727a 121.230b
HDL-cholesterol raloxifene 36.36.1 37.18.1 39.87.3 41.19.9 45.38.5a
Triglycerides raloxifene 179.666.3 18355 18772 18673 19081.3
Abbreviations are: LDL, low-density lipoprotein; HDL, high-density lipoprotein.
a P  0.05 vs. baseline; b P  0.01 vs. baseline (two-tailed, paired Student t test)
understood. In vitro experiments suggest that raloxifene According to the Choices for Healthy Outcomes in Car-
ing for ESRD (CHOICE) study [30], lipid abnormalitieshas different effects from estradiol at the estrogen recep-
tor, including differential modulation of DNA response accounted in 33% of the patients as a risk factor for
cardiovascular disease.elements [26] and induction of a different conforma-
tional change in the transactivation domain of the ligand- It had been thought for many years that estrogen were
cardioprotective; as a result, HRT was routinely pre-binding domain [27]. Preliminary studies in humans sug-
gest that raloxifene may have clinically relevant tissue scribed for both primary and secondary prevention of
coronary heart disease in nonuremic menopausal women.selectivity [9, 28]. A long-term (40 months) clinical trial,
the Multiple Outcomes of Raloxifene Evaluation (MORE) Nevertheless, this presumed protective effect has not
been confirmed in the Women’s Health Initiative Studystudy, involving 7705 postmenopausal women with osteo-
porosis given 60 mg or 120 mg of raloxifene or placebo [6], mostly of primary prevention, and the HERS trials of
secondary prevention [31], suggesting that a continuousdaily, found that raloxifene’s antagonistic effect on the
breast appeared to cause a reduction in the risk of breast estrogen-progestin regimen is ineffective for both pri-
mary and secondary prevention of coronary heart diseasecancer [8]. Raloxifene did not increase the risk of endo-
metrial cancer, but there was an increased incidence of and may increase risk in some patients.
thromboembolic disease, hot flashes, influenza-like symp- The impact of raloxifene on the risk of coronary heart
toms, peripheral edema, and leg cramps. Although our disease in healthy women is not known. Serum LDL
study lasted only 1 year, none of these side effects were and plasma fibrinogen are decreased by raloxifene, while
observed in our patients on raloxifene. Nevertheless, it HDL and triglyceride concentrations are unchanged [32].
is important to mention that patients included in the In the MORE trial, no early increase or overall decrease
study did not have previous history of venous occlusive in cardiovascular events were seen during the 4 years of
disease or vascular accesses thrombosis. In this same therapy [33]. However, in a subset of women at highest
study, 6828 of the women had lumbar spine x-ray films risk for cardiovascular events, risk was significantly re-
at baseline and after 36 months of treatment. Among duced with raloxifene compared with placebo. In our
the women receiving 60 mg raloxifene, 6.6% had new study, the hemodialyzed women on raloxifene exhibited
vertebral fractures, compared with 10.1% in the placebo a significant decrease in LDL-cholesterol of 5.9, 6.8, and
group. Nevertheless, the risk of nonvertebral fractures 12.2% at 6, 9, and 12 months, respectively. These changes
was similar. Lumbar spine and femoral neck bone density were not observed in the placebo group.
increased from 2.0% to 2.7% in the raloxifene groups
compared with placebo.
CONCLUSIONOur study demonstrates that after only 1 year on ralox-
Raloxifene has proven to be an effective drug in termsifene there was a significant increase in trabecular BMD
of bone mineral and lipid metabolism, with no significantwith an important decrease in bone resorption markers.
side effects. The long-term effect of this drug remains toThese changes were not detected in those women on pla-
be analyzed.cebo for the same period of time. Although we have not
evaluated fracture risk data, our results could suggest that
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